RESEARCH GUIDE

Ipamorelin vs GHRP-2 vs GHRP-6 vs Hexarelin

Four GH secretagogues with different selectivity and side-effect profiles in preclinical models.

Growth hormone secretagogues (GHSs) are peptides that stimulate GH release via the ghrelin receptor (GHS-R). They differ in selectivity — which matters because the ghrelin receptor also drives appetite and cortisol/prolactin release. Here is the comparison.

Selectivity comparison

Compound	GH release	Cortisol	Prolactin	Appetite	SMART MD price
Ipamorelin	Moderate	Minimal	Minimal	Minimal	$84.98 (10mg)
GHRP-2	Strong	Moderate	Moderate	Mild	$55.98 (5mg)
GHRP-6	Strong	Mild	Mild	Strong	$58.98 (5mg)
Hexarelin	Very strong	Moderate	Moderate	Minimal	$66.98 (5mg)

Ipamorelin — the selective GHS

Ipamorelin is a pentapeptide designed for GHS-R selectivity — it triggers GH release with minimal effect on cortisol, prolactin, and appetite. This makes it the most research-friendly GHS when the study question is specifically about GH without confounding stress hormone or appetite-axis activation.

Selectivity profile — cleanest GHS in terms of off-target hormone effects in preclinical models
Stack compatibility — most-paired GHS with GHRH analogues (CJC-1295, Tesamorelin) for synergistic GH release
Research context — preferred when isolating pulsatile GH signal

Buy Ipamorelin →

GHRP-2 — strong release, moderate collateral

GHRP-2 is a potent GH secretagogue with stronger GH release than Ipamorelin but greater cortisol and prolactin stimulation. In research contexts where GH magnitude matters more than hormonal selectivity, it produces larger pulses.

Strong GH pulse — higher magnitude than Ipamorelin
Collateral hormones — moderate cortisol and prolactin elevation in preclinical models
Research context — preferred when magnitude of GH release is the primary variable

Buy GHRP-2 →

GHRP-6 — the appetite-stimulating GHS

GHRP-6 activates the ghrelin receptor strongly enough to produce pronounced appetite stimulation in preclinical models — a signature effect not seen with Ipamorelin and less pronounced with GHRP-2. This makes GHRP-6 specifically useful when the research question involves ghrelin-driven appetite pathways.

Appetite signaling — strongest ghrelin-like appetite effect among the four
GH release — strong, comparable to GHRP-2
Research context — used when studying ghrelin-appetite axis or cachexia/underweight models

Buy GHRP-6 →

Hexarelin — the maximum-magnitude GHS

Hexarelin produces the strongest GH release among the four. It has unique cardiovascular research literature — including direct effects on cardiac tissue via CD36-mediated pathways, separate from its GHS-R activity. In chronic preclinical administration models, tachyphylaxis (diminished response over time) is documented.

Strongest GH magnitude among the four compared here
CD36 pathway — unique cardiovascular research applications
Tachyphylaxis — chronic administration models show diminished response over time
Minimal appetite effect unlike GHRP-6

Buy Hexarelin →

Stacking GHS with GHRH analogues

GHS and GHRH peptides activate different receptors (GHS-R and GHRH-R respectively) but both trigger pituitary GH release. Combined, they produce synergistic GH release larger than either alone — this is why GHS + GHRH stacks dominate peptide research literature.

CJC-1295 no-DAC + Ipamorelin

The most-studied GHS + GHRH pairing. Pulsatile GHRH (no DAC) with selective GHS (Ipamorelin). Available pre-dosed at $67.98.

Buy 2X Blend →

Tesamorelin + Ipamorelin

Adiposity-focused stack. Tesamorelin's visceral fat research profile plus Ipamorelin's selective GH release. Pre-dosed 10mg+5mg at $79.99.

Buy 2X Blend →

Frequently asked questions

Which GHS is most selective?+

Ipamorelin is the most GHS-R-selective — producing GH release with minimal cortisol, prolactin, or appetite effects in preclinical models. This makes it the preferred choice when the research question is isolated GH signaling without confounding hormone elevation.

Why does GHRP-6 stimulate appetite?+

GHRP-6 is a potent ghrelin receptor agonist. Ghrelin, the endogenous ligand of GHS-R, is the primary appetite-signaling peptide from the stomach. GHRP-6's activity at this receptor is strong enough to meaningfully stimulate food intake in preclinical models. This is why GHRP-6 is preferred when appetite pathways are the research target.

Can GHSs be stacked with GHRH peptides?+

Yes — GHS + GHRH stacks are the most-studied GH pathway research protocol. The two classes activate different receptors (GHS-R vs GHRH-R) but both trigger GH release. Combined, they produce synergistic GH pulses. Most-common pairings: CJC-1295 (no-DAC) + Ipamorelin, Tesamorelin + Ipamorelin.

Why does Hexarelin cause tachyphylaxis?+

Chronic Hexarelin administration in preclinical models shows diminished GH response over time — a phenomenon called tachyphylaxis. The mechanism involves receptor desensitization and possibly pituitary somatotroph depletion. Research protocols involving chronic dosing need to account for this; pulsed-dosing protocols show less tachyphylaxis.

Are these peptides legal for research?+

Yes. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin are all legal to acquire for research purposes in the United States. They are classified as research-use-only compounds — not for human consumption. Licensed researchers and physicians may acquire them for preclinical research and practice-of-medicine use.

How is purity verified?+

Every SMART MD batch is verified by three independent U.S. laboratories via HPLC, mass spectrometry, and LAL endotoxin testing. Lot-specific COAs are publicly verifiable at smartmdpeptides.com/verify.